- Split View
-
Views
-
Cite
Cite
R. Vanholder, Z. Massy, A. Argiles, G. Spasovski, F. Verbeke, N. Lameire, for the European Uremic Toxin Work Group (EUTox), Chronic kidney disease as cause of cardiovascular morbidity and mortality, Nephrology Dialysis Transplantation, Volume 20, Issue 6, June 2005, Pages 1048–1056, https://doi.org/10.1093/ndt/gfh813
- Share Icon Share
Abstract
To make an evidence-based evaluation of the relationship between kidney failure and cardiovascular risk, we reviewed the literature obtained from a PubMed search using pre-defined keywords related to both conditions and covering 18 years (1986 until end 2003). Eighty-five publications, covering 552 258 subjects, are summarized. All but three studies support a link between kidney dysfunction and cardiovascular risk. More importantly, the association is observed very early during the evolution of renal failure: an accelerated cardiovascular risk appears at varying glomerular filtration rate (GFR) cut-off values, which were ≥60 ml/min in at least 20 studies. Many studies lacked a clear definition of cardiovascular disease and/or used a single determination of serum creatinine or GFR as an index of kidney function, which is not necessarily corresponding to well-defined chronic kidney disease. In six studies, however, chronic kidney dysfunction and cardiovascular disease were well defined and the results of these confirm the impact of kidney dysfunction. It is concluded that there is an undeniable link between kidney dysfunction and cardiovascular risk and that the presence of even subtle kidney dysfunction should be considered as one of the conditions necessitating intensive prevention of this cardiovascular risk.
Introduction
In a landmark publication in 1974, Lindner et al. [1] first pointed out that patients treated by chronic renal replacement therapy are exposed to cardiovascular problems and suffer from accelerated and severe atheromatosis. More recently, the extent of the problem was re-emphasized by Foley et al. [2]. According to these authors, already a 5-fold increase in cardiovascular mortality risk is present in dialysis patients older than 75 years, but, more importantly, cardiovascular mortality is increased approximately 375 times in patients aged between 25 and 35 years [2]. In young adults dialysed for several years during childhood or adolescence, an exceptionally high prevalence of coronary calcifications is found for their age range [3]. In stage 5 chronic kidney disease (CKD) (end-stage), the overall risk for stroke increases 6-fold [4]. In patients with chronic kidney dysfunction, cardiovascular disease (CVD) is twice as common as in the general population and it advances at twice the rate [5]. In an essentially non-dialysed population from the UK with a serum creatinine (SCrea) ≥1.7 mg/dl (≥150 µmol/l), standardized mortality was increased 2-fold vs the general population in those aged >65 years, 12-fold between the ages of 50 and 64 and even 36-fold between the ages of 16 and 49 [6].
Cardiac events in the dialysis population are characterized by a substantial mortality [7–9]. The expected remaining life time is shortened by ≥50% [10]. Life expectancy at the start of dialysis is comparable to, if not worse than, that of many cancers at the time of their diagnosis [11]. Even after successful revascularization for peripheral vascular disease, local recurrence rate is high and early [12].
These observations have an important socio-economic impact. In a multivariate analysis in dialysis patients, angina and peripheral vascular disease were among the most prominent reasons for hospitalization [13]. By the end of 2001, the dialysis population worldwide consisted of close to 1 500 000 patients [14], while it increases by ≥7% each year [14]. End-stage renal disease (ESRD) treatment is expected to cover, worldwide, 2 million patients in 2005 and 2.5 million in 2010. Even if these are seemingly small patient groups, the costs of dialysis, especially if indirect (hidden) costs related to the cardiovascular complications are included, make the socio-economic burden dramatic. More importantly, however, the problem starts long before dialysis is needed and this extends the population at risk ≥100-fold [15] (see below).
Our present study showed that (i) in the presence of an increased SCrea or a decreased glomerular filtration rate (GFR), morbidity and mortality because of CVD are markedly increased and vascular degradation is accelerated; (ii) the process of cardiovascular damage starts very early during progression in well-defined CKD, long before the dialysis stage is reached; (iii) the link between kidney dysfunction and CVD is an important global epidemiological entity with an extent comparable to the link observed between CVD and diabetes mellitus; (iv) apart from traditional cardiovascular risk factors, non-traditional factors specifically related to kidney failure per se, are very likely to play a causative role; (v) adequate preventive measures against CVD should be started early during the natural history of kidney dysfunction, but their application is hampered by the incorrect interpretation of renal function parameters, the delayed identification of kidney failure and the (too) late referral of patients with kidney dysfunction.
The primary aim of the present study was to offer a broad review of available studies referring to an enhanced cardiovascular risk in chronic renal failure patients. The second aim was to define at which stage of renal dysfunction cardiovascular problems were at first perceived.
Subjects and methods
To appreciate the relationship between changes in parameters of kidney function and cardiovascular risk, a literature search (PubMed) was undertaken with as keywords: ‘cardio-vascular or cardiovascular or vascular or atheromatosis or atherosclerosis or atherogenesis or arteriosclerosis or stroke or outcome or survival or mortality’ on one hand and ‘renal or kidney or uremia or uraemia’ on the other. This search was repeated at regular intervals (every 3 months) to update the database, with 31 December 2003 as final publication date for inclusion. In addition, the reference list of the retrieved publications was screened in order to add further missing publications to the database. This approach finally emanated in the retrieval of 85 publications, covering the period 1986–2003 (18 years in total).
The issue of kidney dysfunction as a cardiovascular risk marker was underscored recently in a comprehensive statement [16]. Another recent publication was restricted to reports published in 2003 [17]. Two seminal reviews reported on, respectively, 19 and 16 publications that are included in the present survey [18,19]. The present review extends the previous work by an almost complete retrieval of publications resulting in the identification of 40 additional references [6,20–58].
The retrieval was limited to studies containing at least one population with renal failure which was not yet on dialysis.
In order to avoid selection bias, we intentionally opted to include all retrieved studies, such as (I) studies using renal function as a continuous variable; (II) studies using sCrea as an index of renal function; (III) studies not adjusting for other cardiovascular risk factors; (IV) studies with overall mortality rather than cardiovascular mortality as an endpoint. All these characteristics are specified in Tables 1–3.
Author . | Year . | Selection . | n . | Agea . | F-Ub . | Cut-off . | Cut-off . | Adjuste . |
---|---|---|---|---|---|---|---|---|
. | . | criterion . | . | . | . | clearc . | SCread . | . |
Friedman [32] | 1991 | STR | 492 | >59 | 1.5 | 120.0 (1.36) | Yes | |
Matts [61] | 1993 | MI | 417 | 51 | >7.0 | 80.0 (0.90) | Yes | |
Nygard [33] | 1997 | CHD | 587 | 62 | 4.6 | 120.0 (1.36) | Yes | |
Gottlieb [34]* | 1998 | MI | 201752 | 73 | 2.0 | 124.0 (1.40) | Yes | |
Anderson [84] | 1999 | CABG | 3902 | 64 | 0.1 | 132.6 (1.50) | No | |
McCullough [85]** | 2000 | CCU | 9544 | 63 | 6.7 | 81.5f,g | Yes | |
Brooks [101] | 2000 | CI | 3610 | 62 | 5.0 | NDh | NDh | Yes |
Rubenstein [86] | 2000 | PCI | 3334 | 68 | 4.6 | 132.6 (1.50) | No | |
Beattie [87]** | 2001 | MI | [1724] | 63 | 8.3 | 63.1f,g | Yes | |
Hemmelgarn [88] | 2001 | PCA | 16989 | 2.0 | 203.3 (2.30) | Yes | ||
Schlipak [89] | 2001 | CHD | 2763 | 67 | 4.1 | 60.0f | 106.1 (1.20) | Yes |
Szczech [90] | 2001 | CI | 59576 | 65 | 3.0 | 221.0 (2.50) | Yes | |
Ting [35] | 2001 | PCI | 2626 | 67 | 2.0 | 265.2 (3.00) | Yes | |
Asinger [36] | 2001 | PCI | 154 | 60 | 2.0 | 177.0 (2.00) | No | |
Al Suwaidi [60] | 2002 | CHD | 37925 | 72 | 0.5 | 70.0f | Yes | |
Szczech [59] | 2002 | CHD | 3608 | 63 | 7.0 | 132.6 (1.50) | Yes | |
Best [91] | 2002 | PCI | 5327 | 69 | 3.0 | 70.0f | Yes | |
Beddhu [92]*** | 2002 | PCA | 8600 | 63 | 8.0 | 57.0i | Yes | |
Gruberg [93] | 2002 | PCI | 5084 | 67 | 1.0 | Contf,j | 132.6 (1.50)k | Yes |
124.0 (1.40)l | ||||||||
Januzzi [37] | 2002 | CCU | 1537 | 67 | Tranm | 75.0f | No | |
Wright [94] | 2002 | MI | 3106 | 73 | 5.0 | 75.0f | Yes | |
Walsh [95] | 2002 | MI | 483 | 71 | 1.0 | Contf,g,j | 132.6 (1.50) | Yes |
McCullough [53] | 2002 | CP | 817 | 64 | 0.1 | 47.0f,g | Yes | |
Sorensen [99] | 2002 | MI | 6252 | 69 | 6.0 | 55.0f | Yes | |
Shlipak [100]* | 2002 | MI | [130099] | 77 | 1.0 | 55.0f | 132.6 (1.50) | Yes |
Reis [102] | 2002 | CHD | 784 | 60 | Tranm | 80.0f | 106.1 (1.20) | Yes |
Kaplan [57] | 2002 | MI | 2677 | 64 | 3.4 | 120.0 (1.36) | Yes | |
Gruberg [96] | 2003 | CHD | 1265 | 71 | 1.0 | 50.0f | Yes | |
Reinecke [97] | 2003 | PCI | 1049 | 63 | 3.2 | 115.0 (1.30) | Yes | |
Wison [98] | 2003 | CHD | 2503 | 63 | Tranm | 76.8f,n | Yes | |
Zebrack [38]*** | 2003 | PCA | [1484] | 65 | 3.0 | 60.0i | Yes | |
Reddan [39] | 2003 | CHD | 4584 | 63 | 5.0 | 90.0f | No | |
Keeley [40] | 2003 | CHD | 4758 | 64 | 7.0 | 60.0i | Yes | |
Conlon [41] | 2003 | RAS | 1235 | 4.0 | Contj | Yes | ||
Naidu [42] | 2003 | PCI | 4602 | 64 | 1.0 | Increasedo | Yes | |
HPSCGp[43] | 2003 | OAD | 20536 | 63 | 5.0 | 130.0 (1.47)k | No | |
110.0 (1.25)l | ||||||||
Sadeghi [52] | 2003 | PCI | 1933 | 65 | 1.0 | 60.0f | Yes | |
Langston [54] | 2003 | MI | 508 | 74 | 1.0 | 60.0f | Yes | |
Scolari [55] | 2003 | AERD | 95 | 71 | 7.0 | 50.0i | Yes | |
Hillege [56] | 2003 | MI | 298 | 59 | 1.0 | 81.0f | Yes |
Author . | Year . | Selection . | n . | Agea . | F-Ub . | Cut-off . | Cut-off . | Adjuste . |
---|---|---|---|---|---|---|---|---|
. | . | criterion . | . | . | . | clearc . | SCread . | . |
Friedman [32] | 1991 | STR | 492 | >59 | 1.5 | 120.0 (1.36) | Yes | |
Matts [61] | 1993 | MI | 417 | 51 | >7.0 | 80.0 (0.90) | Yes | |
Nygard [33] | 1997 | CHD | 587 | 62 | 4.6 | 120.0 (1.36) | Yes | |
Gottlieb [34]* | 1998 | MI | 201752 | 73 | 2.0 | 124.0 (1.40) | Yes | |
Anderson [84] | 1999 | CABG | 3902 | 64 | 0.1 | 132.6 (1.50) | No | |
McCullough [85]** | 2000 | CCU | 9544 | 63 | 6.7 | 81.5f,g | Yes | |
Brooks [101] | 2000 | CI | 3610 | 62 | 5.0 | NDh | NDh | Yes |
Rubenstein [86] | 2000 | PCI | 3334 | 68 | 4.6 | 132.6 (1.50) | No | |
Beattie [87]** | 2001 | MI | [1724] | 63 | 8.3 | 63.1f,g | Yes | |
Hemmelgarn [88] | 2001 | PCA | 16989 | 2.0 | 203.3 (2.30) | Yes | ||
Schlipak [89] | 2001 | CHD | 2763 | 67 | 4.1 | 60.0f | 106.1 (1.20) | Yes |
Szczech [90] | 2001 | CI | 59576 | 65 | 3.0 | 221.0 (2.50) | Yes | |
Ting [35] | 2001 | PCI | 2626 | 67 | 2.0 | 265.2 (3.00) | Yes | |
Asinger [36] | 2001 | PCI | 154 | 60 | 2.0 | 177.0 (2.00) | No | |
Al Suwaidi [60] | 2002 | CHD | 37925 | 72 | 0.5 | 70.0f | Yes | |
Szczech [59] | 2002 | CHD | 3608 | 63 | 7.0 | 132.6 (1.50) | Yes | |
Best [91] | 2002 | PCI | 5327 | 69 | 3.0 | 70.0f | Yes | |
Beddhu [92]*** | 2002 | PCA | 8600 | 63 | 8.0 | 57.0i | Yes | |
Gruberg [93] | 2002 | PCI | 5084 | 67 | 1.0 | Contf,j | 132.6 (1.50)k | Yes |
124.0 (1.40)l | ||||||||
Januzzi [37] | 2002 | CCU | 1537 | 67 | Tranm | 75.0f | No | |
Wright [94] | 2002 | MI | 3106 | 73 | 5.0 | 75.0f | Yes | |
Walsh [95] | 2002 | MI | 483 | 71 | 1.0 | Contf,g,j | 132.6 (1.50) | Yes |
McCullough [53] | 2002 | CP | 817 | 64 | 0.1 | 47.0f,g | Yes | |
Sorensen [99] | 2002 | MI | 6252 | 69 | 6.0 | 55.0f | Yes | |
Shlipak [100]* | 2002 | MI | [130099] | 77 | 1.0 | 55.0f | 132.6 (1.50) | Yes |
Reis [102] | 2002 | CHD | 784 | 60 | Tranm | 80.0f | 106.1 (1.20) | Yes |
Kaplan [57] | 2002 | MI | 2677 | 64 | 3.4 | 120.0 (1.36) | Yes | |
Gruberg [96] | 2003 | CHD | 1265 | 71 | 1.0 | 50.0f | Yes | |
Reinecke [97] | 2003 | PCI | 1049 | 63 | 3.2 | 115.0 (1.30) | Yes | |
Wison [98] | 2003 | CHD | 2503 | 63 | Tranm | 76.8f,n | Yes | |
Zebrack [38]*** | 2003 | PCA | [1484] | 65 | 3.0 | 60.0i | Yes | |
Reddan [39] | 2003 | CHD | 4584 | 63 | 5.0 | 90.0f | No | |
Keeley [40] | 2003 | CHD | 4758 | 64 | 7.0 | 60.0i | Yes | |
Conlon [41] | 2003 | RAS | 1235 | 4.0 | Contj | Yes | ||
Naidu [42] | 2003 | PCI | 4602 | 64 | 1.0 | Increasedo | Yes | |
HPSCGp[43] | 2003 | OAD | 20536 | 63 | 5.0 | 130.0 (1.47)k | No | |
110.0 (1.25)l | ||||||||
Sadeghi [52] | 2003 | PCI | 1933 | 65 | 1.0 | 60.0f | Yes | |
Langston [54] | 2003 | MI | 508 | 74 | 1.0 | 60.0f | Yes | |
Scolari [55] | 2003 | AERD | 95 | 71 | 7.0 | 50.0i | Yes | |
Hillege [56] | 2003 | MI | 298 | 59 | 1.0 | 81.0f | Yes |
aAge: mean value, mean of means or medians of different groups, or mean of ranges; lower limit if preceded by ‘>’; bF-U: mean/median follow-up in years; shortest reported follow-up if preceded by ‘>’; ccut-off clear: highest clearance value [creatinine clearance or equivalent of GFR (ml/min)] for which a deterioration in cardiovascular status was observed vs the control (‘normal kidney function’) group; dcut-off SCrea: lowest sCrea value [µmol/l (mg/dl)] for which a deterioration in cardiovascular status was observed vs the control (‘normal kidney function’) group; eadjust: adjustment for comorbid factors; fCockroft–Gault; gnormalized per 72 kg body weight; hND: renal failure not defined; iMDRD formula; jkidney function parameter(s) used as continuous variable; kmen; lwomen; mtrans-sectional study; nnormalized per 1.73 m2; oincreased: the cut-off for kidney failure is an ‘increased’ sCrea without further specification; pHeart Protection Study Collaborative Group [Occlusive Arterial Disease without known diabetes (14 573 subjects) or diabetes mellitus (5963 subjects)].
STR, stroke; MI, myocardial infarction; CHD, coronary heart disease, unstable angina; CCU, admission to the coronary unit; CI, coronary intervention (both CABG and PCI); CP, chest pain; RAS, renal artery stenosis; OAD, occlusive arterial disease; AERD, atheroembolic renal disease.
*–***Both studies were undertaken in the same population or database (*Cooperative Cardiovascular Project; **Henry Ford Hospital Cardiac Intensive Care Unit Database; ***Intermountain Heart Study). Only the study with the highest number of patients is taken into account for calculating the total number of analysed subjects; the omitted numbers are cited in square brackets.
Studies in bold have a cardiovascular endpoint.
Author . | Year . | Selection . | n . | Agea . | F-Ub . | Cut-off . | Cut-off . | Adjuste . |
---|---|---|---|---|---|---|---|---|
. | . | criterion . | . | . | . | clearc . | SCread . | . |
Friedman [32] | 1991 | STR | 492 | >59 | 1.5 | 120.0 (1.36) | Yes | |
Matts [61] | 1993 | MI | 417 | 51 | >7.0 | 80.0 (0.90) | Yes | |
Nygard [33] | 1997 | CHD | 587 | 62 | 4.6 | 120.0 (1.36) | Yes | |
Gottlieb [34]* | 1998 | MI | 201752 | 73 | 2.0 | 124.0 (1.40) | Yes | |
Anderson [84] | 1999 | CABG | 3902 | 64 | 0.1 | 132.6 (1.50) | No | |
McCullough [85]** | 2000 | CCU | 9544 | 63 | 6.7 | 81.5f,g | Yes | |
Brooks [101] | 2000 | CI | 3610 | 62 | 5.0 | NDh | NDh | Yes |
Rubenstein [86] | 2000 | PCI | 3334 | 68 | 4.6 | 132.6 (1.50) | No | |
Beattie [87]** | 2001 | MI | [1724] | 63 | 8.3 | 63.1f,g | Yes | |
Hemmelgarn [88] | 2001 | PCA | 16989 | 2.0 | 203.3 (2.30) | Yes | ||
Schlipak [89] | 2001 | CHD | 2763 | 67 | 4.1 | 60.0f | 106.1 (1.20) | Yes |
Szczech [90] | 2001 | CI | 59576 | 65 | 3.0 | 221.0 (2.50) | Yes | |
Ting [35] | 2001 | PCI | 2626 | 67 | 2.0 | 265.2 (3.00) | Yes | |
Asinger [36] | 2001 | PCI | 154 | 60 | 2.0 | 177.0 (2.00) | No | |
Al Suwaidi [60] | 2002 | CHD | 37925 | 72 | 0.5 | 70.0f | Yes | |
Szczech [59] | 2002 | CHD | 3608 | 63 | 7.0 | 132.6 (1.50) | Yes | |
Best [91] | 2002 | PCI | 5327 | 69 | 3.0 | 70.0f | Yes | |
Beddhu [92]*** | 2002 | PCA | 8600 | 63 | 8.0 | 57.0i | Yes | |
Gruberg [93] | 2002 | PCI | 5084 | 67 | 1.0 | Contf,j | 132.6 (1.50)k | Yes |
124.0 (1.40)l | ||||||||
Januzzi [37] | 2002 | CCU | 1537 | 67 | Tranm | 75.0f | No | |
Wright [94] | 2002 | MI | 3106 | 73 | 5.0 | 75.0f | Yes | |
Walsh [95] | 2002 | MI | 483 | 71 | 1.0 | Contf,g,j | 132.6 (1.50) | Yes |
McCullough [53] | 2002 | CP | 817 | 64 | 0.1 | 47.0f,g | Yes | |
Sorensen [99] | 2002 | MI | 6252 | 69 | 6.0 | 55.0f | Yes | |
Shlipak [100]* | 2002 | MI | [130099] | 77 | 1.0 | 55.0f | 132.6 (1.50) | Yes |
Reis [102] | 2002 | CHD | 784 | 60 | Tranm | 80.0f | 106.1 (1.20) | Yes |
Kaplan [57] | 2002 | MI | 2677 | 64 | 3.4 | 120.0 (1.36) | Yes | |
Gruberg [96] | 2003 | CHD | 1265 | 71 | 1.0 | 50.0f | Yes | |
Reinecke [97] | 2003 | PCI | 1049 | 63 | 3.2 | 115.0 (1.30) | Yes | |
Wison [98] | 2003 | CHD | 2503 | 63 | Tranm | 76.8f,n | Yes | |
Zebrack [38]*** | 2003 | PCA | [1484] | 65 | 3.0 | 60.0i | Yes | |
Reddan [39] | 2003 | CHD | 4584 | 63 | 5.0 | 90.0f | No | |
Keeley [40] | 2003 | CHD | 4758 | 64 | 7.0 | 60.0i | Yes | |
Conlon [41] | 2003 | RAS | 1235 | 4.0 | Contj | Yes | ||
Naidu [42] | 2003 | PCI | 4602 | 64 | 1.0 | Increasedo | Yes | |
HPSCGp[43] | 2003 | OAD | 20536 | 63 | 5.0 | 130.0 (1.47)k | No | |
110.0 (1.25)l | ||||||||
Sadeghi [52] | 2003 | PCI | 1933 | 65 | 1.0 | 60.0f | Yes | |
Langston [54] | 2003 | MI | 508 | 74 | 1.0 | 60.0f | Yes | |
Scolari [55] | 2003 | AERD | 95 | 71 | 7.0 | 50.0i | Yes | |
Hillege [56] | 2003 | MI | 298 | 59 | 1.0 | 81.0f | Yes |
Author . | Year . | Selection . | n . | Agea . | F-Ub . | Cut-off . | Cut-off . | Adjuste . |
---|---|---|---|---|---|---|---|---|
. | . | criterion . | . | . | . | clearc . | SCread . | . |
Friedman [32] | 1991 | STR | 492 | >59 | 1.5 | 120.0 (1.36) | Yes | |
Matts [61] | 1993 | MI | 417 | 51 | >7.0 | 80.0 (0.90) | Yes | |
Nygard [33] | 1997 | CHD | 587 | 62 | 4.6 | 120.0 (1.36) | Yes | |
Gottlieb [34]* | 1998 | MI | 201752 | 73 | 2.0 | 124.0 (1.40) | Yes | |
Anderson [84] | 1999 | CABG | 3902 | 64 | 0.1 | 132.6 (1.50) | No | |
McCullough [85]** | 2000 | CCU | 9544 | 63 | 6.7 | 81.5f,g | Yes | |
Brooks [101] | 2000 | CI | 3610 | 62 | 5.0 | NDh | NDh | Yes |
Rubenstein [86] | 2000 | PCI | 3334 | 68 | 4.6 | 132.6 (1.50) | No | |
Beattie [87]** | 2001 | MI | [1724] | 63 | 8.3 | 63.1f,g | Yes | |
Hemmelgarn [88] | 2001 | PCA | 16989 | 2.0 | 203.3 (2.30) | Yes | ||
Schlipak [89] | 2001 | CHD | 2763 | 67 | 4.1 | 60.0f | 106.1 (1.20) | Yes |
Szczech [90] | 2001 | CI | 59576 | 65 | 3.0 | 221.0 (2.50) | Yes | |
Ting [35] | 2001 | PCI | 2626 | 67 | 2.0 | 265.2 (3.00) | Yes | |
Asinger [36] | 2001 | PCI | 154 | 60 | 2.0 | 177.0 (2.00) | No | |
Al Suwaidi [60] | 2002 | CHD | 37925 | 72 | 0.5 | 70.0f | Yes | |
Szczech [59] | 2002 | CHD | 3608 | 63 | 7.0 | 132.6 (1.50) | Yes | |
Best [91] | 2002 | PCI | 5327 | 69 | 3.0 | 70.0f | Yes | |
Beddhu [92]*** | 2002 | PCA | 8600 | 63 | 8.0 | 57.0i | Yes | |
Gruberg [93] | 2002 | PCI | 5084 | 67 | 1.0 | Contf,j | 132.6 (1.50)k | Yes |
124.0 (1.40)l | ||||||||
Januzzi [37] | 2002 | CCU | 1537 | 67 | Tranm | 75.0f | No | |
Wright [94] | 2002 | MI | 3106 | 73 | 5.0 | 75.0f | Yes | |
Walsh [95] | 2002 | MI | 483 | 71 | 1.0 | Contf,g,j | 132.6 (1.50) | Yes |
McCullough [53] | 2002 | CP | 817 | 64 | 0.1 | 47.0f,g | Yes | |
Sorensen [99] | 2002 | MI | 6252 | 69 | 6.0 | 55.0f | Yes | |
Shlipak [100]* | 2002 | MI | [130099] | 77 | 1.0 | 55.0f | 132.6 (1.50) | Yes |
Reis [102] | 2002 | CHD | 784 | 60 | Tranm | 80.0f | 106.1 (1.20) | Yes |
Kaplan [57] | 2002 | MI | 2677 | 64 | 3.4 | 120.0 (1.36) | Yes | |
Gruberg [96] | 2003 | CHD | 1265 | 71 | 1.0 | 50.0f | Yes | |
Reinecke [97] | 2003 | PCI | 1049 | 63 | 3.2 | 115.0 (1.30) | Yes | |
Wison [98] | 2003 | CHD | 2503 | 63 | Tranm | 76.8f,n | Yes | |
Zebrack [38]*** | 2003 | PCA | [1484] | 65 | 3.0 | 60.0i | Yes | |
Reddan [39] | 2003 | CHD | 4584 | 63 | 5.0 | 90.0f | No | |
Keeley [40] | 2003 | CHD | 4758 | 64 | 7.0 | 60.0i | Yes | |
Conlon [41] | 2003 | RAS | 1235 | 4.0 | Contj | Yes | ||
Naidu [42] | 2003 | PCI | 4602 | 64 | 1.0 | Increasedo | Yes | |
HPSCGp[43] | 2003 | OAD | 20536 | 63 | 5.0 | 130.0 (1.47)k | No | |
110.0 (1.25)l | ||||||||
Sadeghi [52] | 2003 | PCI | 1933 | 65 | 1.0 | 60.0f | Yes | |
Langston [54] | 2003 | MI | 508 | 74 | 1.0 | 60.0f | Yes | |
Scolari [55] | 2003 | AERD | 95 | 71 | 7.0 | 50.0i | Yes | |
Hillege [56] | 2003 | MI | 298 | 59 | 1.0 | 81.0f | Yes |
aAge: mean value, mean of means or medians of different groups, or mean of ranges; lower limit if preceded by ‘>’; bF-U: mean/median follow-up in years; shortest reported follow-up if preceded by ‘>’; ccut-off clear: highest clearance value [creatinine clearance or equivalent of GFR (ml/min)] for which a deterioration in cardiovascular status was observed vs the control (‘normal kidney function’) group; dcut-off SCrea: lowest sCrea value [µmol/l (mg/dl)] for which a deterioration in cardiovascular status was observed vs the control (‘normal kidney function’) group; eadjust: adjustment for comorbid factors; fCockroft–Gault; gnormalized per 72 kg body weight; hND: renal failure not defined; iMDRD formula; jkidney function parameter(s) used as continuous variable; kmen; lwomen; mtrans-sectional study; nnormalized per 1.73 m2; oincreased: the cut-off for kidney failure is an ‘increased’ sCrea without further specification; pHeart Protection Study Collaborative Group [Occlusive Arterial Disease without known diabetes (14 573 subjects) or diabetes mellitus (5963 subjects)].
STR, stroke; MI, myocardial infarction; CHD, coronary heart disease, unstable angina; CCU, admission to the coronary unit; CI, coronary intervention (both CABG and PCI); CP, chest pain; RAS, renal artery stenosis; OAD, occlusive arterial disease; AERD, atheroembolic renal disease.
*–***Both studies were undertaken in the same population or database (*Cooperative Cardiovascular Project; **Henry Ford Hospital Cardiac Intensive Care Unit Database; ***Intermountain Heart Study). Only the study with the highest number of patients is taken into account for calculating the total number of analysed subjects; the omitted numbers are cited in square brackets.
Studies in bold have a cardiovascular endpoint.
Author . | Year . | Selection . | n . | Agea . | F-Ub . | Cut-off . | Cut-off . | Adjuste . |
---|---|---|---|---|---|---|---|---|
. | . | criterion . | . | . | . | clearc . | SCread . | . |
A. Cardiovascular risk factor | ||||||||
Bulpitt [20] | 1986 | HT | 5451 | 51 | 4.3 | Contj | Yes | |
Schulman [63] | 1989 | HT | 10940 | 50 | 5.0 | 150.4 (1.70) | Yes | |
Flack [64] | 1993 | HT | 4830 | 46 | 6.0 | Contj | Yes | |
Rossing [24] | 1996 | DM | 939 | 39 | 10.0 | Contj | Yes | |
Pahor [25] | 1998 | HT | 4336 | 72 | 4.0 | 101.7 (1.15) | No | |
Mann [105] | 2001 | DMq | 9287 | 67 | 4.5 | 65.0f | 124.0 (1.40) | Yes |
Ruilope [62] | 2001 | HT | 18591 | 63 | 3.8 | 60.0f | 132.6 (1.50) | Yes |
Schillaci [106] | 2001 | HT | 1829 | 51 | 4.0 | 83.0 (0.94)k | Yes | |
70.0 (0.79)l | ||||||||
Wang [31] | 2001 | HT | 1880 | 67 | 3.0 | 80.0 (0.90) | Yes | |
De Leeuw [108] | 2002 | HT | 4688 | 70 | 4.1 | 90.0 (1.02) | Yes | |
B. Chronic heart failure | ||||||||
Packer [21] | 1991 | CHF | 1088 | 64 | 1.5 | 115.0 (1.30) | No | |
Madsen [22] | 1994 | CHF | 190 | 66 | 2.1 | 121.0 (1.37) | No | |
Spinar [23] | 1996 | CHF | 300 | 58 | 1.0 | Contj | Yes | |
Feenstra [26] | 1998 | CHF | 2246 | 77 | 0.4 | 115.0 (1.30) | Yes | |
McAlister [27] | 1999 | CHF | 566 | 66 | 1.4 | 130.0 (1.47) | Yes | |
Opasich [28] | 2000 | CHF | 3327 | 64 | 1.0 | 221.0 (2.50) | Yes | |
Dries [103]* | 2000 | LVD | [5834] | 63 | 2.8 | 60.0f | Yes | |
Cowie [29] | 2000 | CHF | 220 | 76 | 1.3 | Contj | Yes | |
Hillege [104] | 2000 | CHF | 1906 | 65 | 3.3 | 76.0f | Yes | |
Al Ahmad [30]* | 2001 | LVD | 6635 | 60 | 2.8 | 75.0i,n | 221.0 (2.50) | Yes |
Mahon [107] | 2002 | CHF | 585 | 65 | 2.6 | 63.9f | Yes | |
Kearney [109] | 2002 | CHF | 553 | 63 | 5.0 | 111.0 (1.26) | Yes | |
McClellan [110] | 2002 | CHF | 646 | 76 | 1.0 | 132.6 (1.50)k | Yes | |
124.0 (1.40)l | ||||||||
C. Aged | ||||||||
Damsgaard [44] | 1990 | Age | 216 | 67 | 6.0 | Contj | Yes | |
Manolio [111]** | 1996 | Age | [5201] | 74 | 3.3 | 132.6 (1.50) | Yes | |
Alcorn [45]** | 1996 | Age | [4575] | >65 | 5.0 | 80.0 (0.90) | Yes | |
Fried [112]** | 1998 | Age | [5201] | 73 | 5.0 | 106.1 (1.20) | Yes | |
Bursztyn [46] | 1999 | Age | 448 | 70 | 6.5 | Contj | Yes | |
Schlipak [113]** | 2002 | Age | 5808 | 75 | Tranm | 60.0f | 132.6 (1.50)k | Yes |
115.0 (1.30)l | ||||||||
Manjunath [65]** | 2003 | Age | [4893] | 73 | 4.3 | 90.0i,n | Yes | |
Fried [47]** | 2003 | Age | [5808] | 74 | 7.3 | 97.3 (1.10) | Yes |
Author . | Year . | Selection . | n . | Agea . | F-Ub . | Cut-off . | Cut-off . | Adjuste . |
---|---|---|---|---|---|---|---|---|
. | . | criterion . | . | . | . | clearc . | SCread . | . |
A. Cardiovascular risk factor | ||||||||
Bulpitt [20] | 1986 | HT | 5451 | 51 | 4.3 | Contj | Yes | |
Schulman [63] | 1989 | HT | 10940 | 50 | 5.0 | 150.4 (1.70) | Yes | |
Flack [64] | 1993 | HT | 4830 | 46 | 6.0 | Contj | Yes | |
Rossing [24] | 1996 | DM | 939 | 39 | 10.0 | Contj | Yes | |
Pahor [25] | 1998 | HT | 4336 | 72 | 4.0 | 101.7 (1.15) | No | |
Mann [105] | 2001 | DMq | 9287 | 67 | 4.5 | 65.0f | 124.0 (1.40) | Yes |
Ruilope [62] | 2001 | HT | 18591 | 63 | 3.8 | 60.0f | 132.6 (1.50) | Yes |
Schillaci [106] | 2001 | HT | 1829 | 51 | 4.0 | 83.0 (0.94)k | Yes | |
70.0 (0.79)l | ||||||||
Wang [31] | 2001 | HT | 1880 | 67 | 3.0 | 80.0 (0.90) | Yes | |
De Leeuw [108] | 2002 | HT | 4688 | 70 | 4.1 | 90.0 (1.02) | Yes | |
B. Chronic heart failure | ||||||||
Packer [21] | 1991 | CHF | 1088 | 64 | 1.5 | 115.0 (1.30) | No | |
Madsen [22] | 1994 | CHF | 190 | 66 | 2.1 | 121.0 (1.37) | No | |
Spinar [23] | 1996 | CHF | 300 | 58 | 1.0 | Contj | Yes | |
Feenstra [26] | 1998 | CHF | 2246 | 77 | 0.4 | 115.0 (1.30) | Yes | |
McAlister [27] | 1999 | CHF | 566 | 66 | 1.4 | 130.0 (1.47) | Yes | |
Opasich [28] | 2000 | CHF | 3327 | 64 | 1.0 | 221.0 (2.50) | Yes | |
Dries [103]* | 2000 | LVD | [5834] | 63 | 2.8 | 60.0f | Yes | |
Cowie [29] | 2000 | CHF | 220 | 76 | 1.3 | Contj | Yes | |
Hillege [104] | 2000 | CHF | 1906 | 65 | 3.3 | 76.0f | Yes | |
Al Ahmad [30]* | 2001 | LVD | 6635 | 60 | 2.8 | 75.0i,n | 221.0 (2.50) | Yes |
Mahon [107] | 2002 | CHF | 585 | 65 | 2.6 | 63.9f | Yes | |
Kearney [109] | 2002 | CHF | 553 | 63 | 5.0 | 111.0 (1.26) | Yes | |
McClellan [110] | 2002 | CHF | 646 | 76 | 1.0 | 132.6 (1.50)k | Yes | |
124.0 (1.40)l | ||||||||
C. Aged | ||||||||
Damsgaard [44] | 1990 | Age | 216 | 67 | 6.0 | Contj | Yes | |
Manolio [111]** | 1996 | Age | [5201] | 74 | 3.3 | 132.6 (1.50) | Yes | |
Alcorn [45]** | 1996 | Age | [4575] | >65 | 5.0 | 80.0 (0.90) | Yes | |
Fried [112]** | 1998 | Age | [5201] | 73 | 5.0 | 106.1 (1.20) | Yes | |
Bursztyn [46] | 1999 | Age | 448 | 70 | 6.5 | Contj | Yes | |
Schlipak [113]** | 2002 | Age | 5808 | 75 | Tranm | 60.0f | 132.6 (1.50)k | Yes |
115.0 (1.30)l | ||||||||
Manjunath [65]** | 2003 | Age | [4893] | 73 | 4.3 | 90.0i,n | Yes | |
Fried [47]** | 2003 | Age | [5808] | 74 | 7.3 | 97.3 (1.10) | Yes |
a–e, i–nFor explanation refer to Table 1; qdiabetes mellitus and/or CVD.
HT, hypertension; DM, diabetes mellitus; CHF, chronic heart failure; LVD, left ventricular dysfunction.
*Both studies were undertaken in the same population or database (SOLVD). **All six studies were undertaken in the same population or database (Cardiovascular Health Study). Only the study with the highest number of patients is taken into account for calculating the total number of analysed subjects; the omitted numbers are cited in square brackets.
Studies in bold have a cardiovascular endpoint.
Author . | Year . | Selection . | n . | Agea . | F-Ub . | Cut-off . | Cut-off . | Adjuste . |
---|---|---|---|---|---|---|---|---|
. | . | criterion . | . | . | . | clearc . | SCread . | . |
A. Cardiovascular risk factor | ||||||||
Bulpitt [20] | 1986 | HT | 5451 | 51 | 4.3 | Contj | Yes | |
Schulman [63] | 1989 | HT | 10940 | 50 | 5.0 | 150.4 (1.70) | Yes | |
Flack [64] | 1993 | HT | 4830 | 46 | 6.0 | Contj | Yes | |
Rossing [24] | 1996 | DM | 939 | 39 | 10.0 | Contj | Yes | |
Pahor [25] | 1998 | HT | 4336 | 72 | 4.0 | 101.7 (1.15) | No | |
Mann [105] | 2001 | DMq | 9287 | 67 | 4.5 | 65.0f | 124.0 (1.40) | Yes |
Ruilope [62] | 2001 | HT | 18591 | 63 | 3.8 | 60.0f | 132.6 (1.50) | Yes |
Schillaci [106] | 2001 | HT | 1829 | 51 | 4.0 | 83.0 (0.94)k | Yes | |
70.0 (0.79)l | ||||||||
Wang [31] | 2001 | HT | 1880 | 67 | 3.0 | 80.0 (0.90) | Yes | |
De Leeuw [108] | 2002 | HT | 4688 | 70 | 4.1 | 90.0 (1.02) | Yes | |
B. Chronic heart failure | ||||||||
Packer [21] | 1991 | CHF | 1088 | 64 | 1.5 | 115.0 (1.30) | No | |
Madsen [22] | 1994 | CHF | 190 | 66 | 2.1 | 121.0 (1.37) | No | |
Spinar [23] | 1996 | CHF | 300 | 58 | 1.0 | Contj | Yes | |
Feenstra [26] | 1998 | CHF | 2246 | 77 | 0.4 | 115.0 (1.30) | Yes | |
McAlister [27] | 1999 | CHF | 566 | 66 | 1.4 | 130.0 (1.47) | Yes | |
Opasich [28] | 2000 | CHF | 3327 | 64 | 1.0 | 221.0 (2.50) | Yes | |
Dries [103]* | 2000 | LVD | [5834] | 63 | 2.8 | 60.0f | Yes | |
Cowie [29] | 2000 | CHF | 220 | 76 | 1.3 | Contj | Yes | |
Hillege [104] | 2000 | CHF | 1906 | 65 | 3.3 | 76.0f | Yes | |
Al Ahmad [30]* | 2001 | LVD | 6635 | 60 | 2.8 | 75.0i,n | 221.0 (2.50) | Yes |
Mahon [107] | 2002 | CHF | 585 | 65 | 2.6 | 63.9f | Yes | |
Kearney [109] | 2002 | CHF | 553 | 63 | 5.0 | 111.0 (1.26) | Yes | |
McClellan [110] | 2002 | CHF | 646 | 76 | 1.0 | 132.6 (1.50)k | Yes | |
124.0 (1.40)l | ||||||||
C. Aged | ||||||||
Damsgaard [44] | 1990 | Age | 216 | 67 | 6.0 | Contj | Yes | |
Manolio [111]** | 1996 | Age | [5201] | 74 | 3.3 | 132.6 (1.50) | Yes | |
Alcorn [45]** | 1996 | Age | [4575] | >65 | 5.0 | 80.0 (0.90) | Yes | |
Fried [112]** | 1998 | Age | [5201] | 73 | 5.0 | 106.1 (1.20) | Yes | |
Bursztyn [46] | 1999 | Age | 448 | 70 | 6.5 | Contj | Yes | |
Schlipak [113]** | 2002 | Age | 5808 | 75 | Tranm | 60.0f | 132.6 (1.50)k | Yes |
115.0 (1.30)l | ||||||||
Manjunath [65]** | 2003 | Age | [4893] | 73 | 4.3 | 90.0i,n | Yes | |
Fried [47]** | 2003 | Age | [5808] | 74 | 7.3 | 97.3 (1.10) | Yes |
Author . | Year . | Selection . | n . | Agea . | F-Ub . | Cut-off . | Cut-off . | Adjuste . |
---|---|---|---|---|---|---|---|---|
. | . | criterion . | . | . | . | clearc . | SCread . | . |
A. Cardiovascular risk factor | ||||||||
Bulpitt [20] | 1986 | HT | 5451 | 51 | 4.3 | Contj | Yes | |
Schulman [63] | 1989 | HT | 10940 | 50 | 5.0 | 150.4 (1.70) | Yes | |
Flack [64] | 1993 | HT | 4830 | 46 | 6.0 | Contj | Yes | |
Rossing [24] | 1996 | DM | 939 | 39 | 10.0 | Contj | Yes | |
Pahor [25] | 1998 | HT | 4336 | 72 | 4.0 | 101.7 (1.15) | No | |
Mann [105] | 2001 | DMq | 9287 | 67 | 4.5 | 65.0f | 124.0 (1.40) | Yes |
Ruilope [62] | 2001 | HT | 18591 | 63 | 3.8 | 60.0f | 132.6 (1.50) | Yes |
Schillaci [106] | 2001 | HT | 1829 | 51 | 4.0 | 83.0 (0.94)k | Yes | |
70.0 (0.79)l | ||||||||
Wang [31] | 2001 | HT | 1880 | 67 | 3.0 | 80.0 (0.90) | Yes | |
De Leeuw [108] | 2002 | HT | 4688 | 70 | 4.1 | 90.0 (1.02) | Yes | |
B. Chronic heart failure | ||||||||
Packer [21] | 1991 | CHF | 1088 | 64 | 1.5 | 115.0 (1.30) | No | |
Madsen [22] | 1994 | CHF | 190 | 66 | 2.1 | 121.0 (1.37) | No | |
Spinar [23] | 1996 | CHF | 300 | 58 | 1.0 | Contj | Yes | |
Feenstra [26] | 1998 | CHF | 2246 | 77 | 0.4 | 115.0 (1.30) | Yes | |
McAlister [27] | 1999 | CHF | 566 | 66 | 1.4 | 130.0 (1.47) | Yes | |
Opasich [28] | 2000 | CHF | 3327 | 64 | 1.0 | 221.0 (2.50) | Yes | |
Dries [103]* | 2000 | LVD | [5834] | 63 | 2.8 | 60.0f | Yes | |
Cowie [29] | 2000 | CHF | 220 | 76 | 1.3 | Contj | Yes | |
Hillege [104] | 2000 | CHF | 1906 | 65 | 3.3 | 76.0f | Yes | |
Al Ahmad [30]* | 2001 | LVD | 6635 | 60 | 2.8 | 75.0i,n | 221.0 (2.50) | Yes |
Mahon [107] | 2002 | CHF | 585 | 65 | 2.6 | 63.9f | Yes | |
Kearney [109] | 2002 | CHF | 553 | 63 | 5.0 | 111.0 (1.26) | Yes | |
McClellan [110] | 2002 | CHF | 646 | 76 | 1.0 | 132.6 (1.50)k | Yes | |
124.0 (1.40)l | ||||||||
C. Aged | ||||||||
Damsgaard [44] | 1990 | Age | 216 | 67 | 6.0 | Contj | Yes | |
Manolio [111]** | 1996 | Age | [5201] | 74 | 3.3 | 132.6 (1.50) | Yes | |
Alcorn [45]** | 1996 | Age | [4575] | >65 | 5.0 | 80.0 (0.90) | Yes | |
Fried [112]** | 1998 | Age | [5201] | 73 | 5.0 | 106.1 (1.20) | Yes | |
Bursztyn [46] | 1999 | Age | 448 | 70 | 6.5 | Contj | Yes | |
Schlipak [113]** | 2002 | Age | 5808 | 75 | Tranm | 60.0f | 132.6 (1.50)k | Yes |
115.0 (1.30)l | ||||||||
Manjunath [65]** | 2003 | Age | [4893] | 73 | 4.3 | 90.0i,n | Yes | |
Fried [47]** | 2003 | Age | [5808] | 74 | 7.3 | 97.3 (1.10) | Yes |
a–e, i–nFor explanation refer to Table 1; qdiabetes mellitus and/or CVD.
HT, hypertension; DM, diabetes mellitus; CHF, chronic heart failure; LVD, left ventricular dysfunction.
*Both studies were undertaken in the same population or database (SOLVD). **All six studies were undertaken in the same population or database (Cardiovascular Health Study). Only the study with the highest number of patients is taken into account for calculating the total number of analysed subjects; the omitted numbers are cited in square brackets.
Studies in bold have a cardiovascular endpoint.
Author . | Year . | Selection . | n . | Agea . | F-Ub . | Cut-off . | Cut-off . | Adjuste . |
---|---|---|---|---|---|---|---|---|
. | . | criterion . | . | . | . | clearc . | SCread . | . |
A. Studies in known chronic renal failure | ||||||||
Jungers [48]r | 1997 | – | 147 | 65 | 5.4 | 50.0f,n | Yes | |
Jungers [49]r | 1998 | – | 980 | 63 | Nors | 50.0f,n | No | |
Levin [50]r | 2001 | – | 313 | 56 | Tranm | 75.0f | No | |
Landray [120]r | 2001 | – | 369 | 62 | Tranm | 44.0f | 130.0 (1.47) | No |
Sarnak [121]r | 2002 | – | 1342 | 50 | Tranm | Contj,t | No | |
Drey [6] | 2003 | – | 1076 | 5.5 | 300.9 (3.40) | Yes | ||
B. Studies based on a single determination of renal function | ||||||||
Wannamethee [114] | 1997 | – | 7690 | 50 | 14.7 | 116.0 (1.31) | Yes | |
Culleton [115] | 1999 | – | 2837 | 54 | 11.0 | 132.6 (1.50)u | Yes | |
Garg [116] | 2002 | – | 2352 | 16.1 | 122.0 (1.38)k | Yesv | ||
104.0 (1.18)l | ||||||||
Muntner [117] | 2002 | – | 6354 | 55 | 14.0 | 90.0i | Yes | |
Henry [118] | 2002 | – | 631 | 64 | 8.7 | 72.2i,n | Yes | |
Manjunath [119]* | 2003 | – | 15350 | 56 | 6.2 | 90.0i,n | Yes | |
Abramson [51]* | 2003 | – | [13716] | 54 | Nors | 60.0f | Yes | |
Jurkovitz [58]* | 2003 | – | [13329] | 54 | Nors | 132.6 (1.50)k | Yes | |
106.1 (1.20)l |
Author . | Year . | Selection . | n . | Agea . | F-Ub . | Cut-off . | Cut-off . | Adjuste . |
---|---|---|---|---|---|---|---|---|
. | . | criterion . | . | . | . | clearc . | SCread . | . |
A. Studies in known chronic renal failure | ||||||||
Jungers [48]r | 1997 | – | 147 | 65 | 5.4 | 50.0f,n | Yes | |
Jungers [49]r | 1998 | – | 980 | 63 | Nors | 50.0f,n | No | |
Levin [50]r | 2001 | – | 313 | 56 | Tranm | 75.0f | No | |
Landray [120]r | 2001 | – | 369 | 62 | Tranm | 44.0f | 130.0 (1.47) | No |
Sarnak [121]r | 2002 | – | 1342 | 50 | Tranm | Contj,t | No | |
Drey [6] | 2003 | – | 1076 | 5.5 | 300.9 (3.40) | Yes | ||
B. Studies based on a single determination of renal function | ||||||||
Wannamethee [114] | 1997 | – | 7690 | 50 | 14.7 | 116.0 (1.31) | Yes | |
Culleton [115] | 1999 | – | 2837 | 54 | 11.0 | 132.6 (1.50)u | Yes | |
Garg [116] | 2002 | – | 2352 | 16.1 | 122.0 (1.38)k | Yesv | ||
104.0 (1.18)l | ||||||||
Muntner [117] | 2002 | – | 6354 | 55 | 14.0 | 90.0i | Yes | |
Henry [118] | 2002 | – | 631 | 64 | 8.7 | 72.2i,n | Yes | |
Manjunath [119]* | 2003 | – | 15350 | 56 | 6.2 | 90.0i,n | Yes | |
Abramson [51]* | 2003 | – | [13716] | 54 | Nors | 60.0f | Yes | |
Jurkovitz [58]* | 2003 | – | [13329] | 54 | Nors | 132.6 (1.50)k | Yes | |
106.1 (1.20)l |
a–e, i–nFor explanation refer to Table 1; rthese studies contained no real control group, but incidence of CVD was strikingly higher than in the general population; srisk rates normalized per number of observation years; tGFR; usignificant relationship with kidney failure only in men; vsignificant relation disappeared after adjustment for traditional risk factors.
*All three studies were undertaken in the same population or database (ARIC). Only the study with the highest number of patients is taken into account for calculating the total number of analysed subjects; the omitted numbers are cited in square brackets.
Studies in bold have a cardiovascular endpoint.
Author . | Year . | Selection . | n . | Agea . | F-Ub . | Cut-off . | Cut-off . | Adjuste . |
---|---|---|---|---|---|---|---|---|
. | . | criterion . | . | . | . | clearc . | SCread . | . |
A. Studies in known chronic renal failure | ||||||||
Jungers [48]r | 1997 | – | 147 | 65 | 5.4 | 50.0f,n | Yes | |
Jungers [49]r | 1998 | – | 980 | 63 | Nors | 50.0f,n | No | |
Levin [50]r | 2001 | – | 313 | 56 | Tranm | 75.0f | No | |
Landray [120]r | 2001 | – | 369 | 62 | Tranm | 44.0f | 130.0 (1.47) | No |
Sarnak [121]r | 2002 | – | 1342 | 50 | Tranm | Contj,t | No | |
Drey [6] | 2003 | – | 1076 | 5.5 | 300.9 (3.40) | Yes | ||
B. Studies based on a single determination of renal function | ||||||||
Wannamethee [114] | 1997 | – | 7690 | 50 | 14.7 | 116.0 (1.31) | Yes | |
Culleton [115] | 1999 | – | 2837 | 54 | 11.0 | 132.6 (1.50)u | Yes | |
Garg [116] | 2002 | – | 2352 | 16.1 | 122.0 (1.38)k | Yesv | ||
104.0 (1.18)l | ||||||||
Muntner [117] | 2002 | – | 6354 | 55 | 14.0 | 90.0i | Yes | |
Henry [118] | 2002 | – | 631 | 64 | 8.7 | 72.2i,n | Yes | |
Manjunath [119]* | 2003 | – | 15350 | 56 | 6.2 | 90.0i,n | Yes | |
Abramson [51]* | 2003 | – | [13716] | 54 | Nors | 60.0f | Yes | |
Jurkovitz [58]* | 2003 | – | [13329] | 54 | Nors | 132.6 (1.50)k | Yes | |
106.1 (1.20)l |
Author . | Year . | Selection . | n . | Agea . | F-Ub . | Cut-off . | Cut-off . | Adjuste . |
---|---|---|---|---|---|---|---|---|
. | . | criterion . | . | . | . | clearc . | SCread . | . |
A. Studies in known chronic renal failure | ||||||||
Jungers [48]r | 1997 | – | 147 | 65 | 5.4 | 50.0f,n | Yes | |
Jungers [49]r | 1998 | – | 980 | 63 | Nors | 50.0f,n | No | |
Levin [50]r | 2001 | – | 313 | 56 | Tranm | 75.0f | No | |
Landray [120]r | 2001 | – | 369 | 62 | Tranm | 44.0f | 130.0 (1.47) | No |
Sarnak [121]r | 2002 | – | 1342 | 50 | Tranm | Contj,t | No | |
Drey [6] | 2003 | – | 1076 | 5.5 | 300.9 (3.40) | Yes | ||
B. Studies based on a single determination of renal function | ||||||||
Wannamethee [114] | 1997 | – | 7690 | 50 | 14.7 | 116.0 (1.31) | Yes | |
Culleton [115] | 1999 | – | 2837 | 54 | 11.0 | 132.6 (1.50)u | Yes | |
Garg [116] | 2002 | – | 2352 | 16.1 | 122.0 (1.38)k | Yesv | ||
104.0 (1.18)l | ||||||||
Muntner [117] | 2002 | – | 6354 | 55 | 14.0 | 90.0i | Yes | |
Henry [118] | 2002 | – | 631 | 64 | 8.7 | 72.2i,n | Yes | |
Manjunath [119]* | 2003 | – | 15350 | 56 | 6.2 | 90.0i,n | Yes | |
Abramson [51]* | 2003 | – | [13716] | 54 | Nors | 60.0f | Yes | |
Jurkovitz [58]* | 2003 | – | [13329] | 54 | Nors | 132.6 (1.50)k | Yes | |
106.1 (1.20)l |
a–e, i–nFor explanation refer to Table 1; rthese studies contained no real control group, but incidence of CVD was strikingly higher than in the general population; srisk rates normalized per number of observation years; tGFR; usignificant relationship with kidney failure only in men; vsignificant relation disappeared after adjustment for traditional risk factors.
*All three studies were undertaken in the same population or database (ARIC). Only the study with the highest number of patients is taken into account for calculating the total number of analysed subjects; the omitted numbers are cited in square brackets.
Studies in bold have a cardiovascular endpoint.
Likewise, no selection of cardiovascular endpoints was pursued and studies were included based on all possible endpoints, such as stroke, transient ischaemic attacks, myocardial infarction; coronary heart disease; unstable angina; coronary intervention (both surgical or percutaneous); admission to the coronary unit; vascular stenosis; atheroembolic disease; and cardiac death.
Studies were classified according to whether they had been conducted in patients with proven CVD, hypertension or chronic heart failure. Studies conducted in the elderly (>65 years old) were classified separately if patients were selected because of this age rather than because of one of the above-mentioned other risk factors together with age. A last separate set of studies was defined as having been undertaken in entirely unselected populations. These were still subdivided in two separate subgroups, one in known chronic renal failure patients and one based on one single renal function determination.
The primary endpoints of the studies contained in this survey are cardiovascular morbidity and mortality as well as overall mortality; in studies evaluating overall and cardiovascular mortality together, both showed remarkably parallel trends [47,55,59–65]. Those studies specifically focusing on cardiovascular morbidity or mortality are highlighted in bold in the corresponding tables (Tables 1–3).
Studies with as endpoints non-cardiovascular events or events only partially or indirectly related to CVD [66–79] and studies in transplant recipients were excluded [80–82], although also these studies convincingly pointed to a relation with kidney dysfunction (17 studies covering 366 720 subjects). The following were considered as only partially or indirectly related to CVD: ventilation time, length of stay in the coronary care unit, post-operative stay, need for blood transfusion, bleeding, overall adverse events, cardiac arrhythmia or immediate in-hospital mortality following vascular surgery or intervention, acute coronary syndrome, general or heart valve surgery or admission to the coronary care unit.
Studies on the relationship of proteinuria/albuminuria with CVD [83] were also considered to be beyond the scope of this survey, although such a relationship is increasingly being recognized [16].
For those studies determining relative mortality risk (RR) in function of GFR, those two factors were correlated with each other in a separate analysis. A separated regression analysis was undertaken for those studies in which RR was close to 1 and in those with an overt increased mortality. The confluence point of the two regression lines was plotted. Data referring to clearance analysis by Cockroft and Gault or by the modification of diet in renal disease (MDRD) formula and data from studies in which adjustments were made for other cardiovascular risk factors were identified by specific symbols and analysed separately. Data from 24 studies were submitted to this analysis.
It should be realized that there are a number of limitations to our present approach, such as the unlimited introduction of publications into the database without selection and the descriptive aim pursuing an encyclopaedic listing of related studies rather than aiming at an in-depth pathophysiological interpretation of the reported data. Furthermore, the approach did not follow the rigid conditions requested for a meta-analysis.
Results
Studies in populations selected on the presence of proven CVD
Data are presented in Table 1.
In this section, 40 studies are included, representing 425 312 patients [32–43,52–57,59–61,84–102]. Of these studies, 19/40 (47.5%) had overall mortality as an endpoint, compared with 21/40 (52.5%) studies with cardiovascular morbidity or mortality as an endpoint. The cardiovascular conditions used to define this population were coronary heart disease in nine studies (22.5%), myocardial infarction in 10 studies (25.0%), percutaneous coronary intervention (PCI) in eight studies (20.0%), post-coronary angiography (PCA) in three studies (7.5%), admission in the coronary care unit and coronary intervention [both PCI and coronary artery bypass graft (CABG)], each in two studies (5.0%), and renal artery stenosis, chest pain, occlusive arterial disease, atheroembolic renal disease, left CABG and stroke, each in one study (2.5%).
Considering these studies together, median age was 64 years (range: 51–77 years) and median follow-up time was 3 years (range: 0.1–8.3 years). The median cut-off value of renal function linked to an increased cardiovascular risk was 60.0 ml/min for GFR or one of its surrogates (calculations according to Cockroft and Gault or one of the MDRD formulae) (highest value: 90.0 ml/min) [39] and 1.47 mg/dl (131.3 µmol/l) for SCrea [lowest value: 0.90 mg/dl (80 µmol/l); values in men and women combined] [61]. The median of the values linked to an increased cardiovascular risk for the MDRD formula (57 ml/min) was slightly lower than for the Cockroft and Gault formula (65.5 ml/min), reflecting the divergent clinical and mathematical bases for both formulae. The results of 34 studies (85.0%) were adjusted for other cardiovascular risk factors.
The first publication for this specific subgroup was published in 1991, when Friedman et al. [32] described that survival was more compromised with a higher SCrea, in 492 elderly subjects post-stroke.
The study by Shlipak et al. [89] published in 2001 and the one by Reis et al. [102] were restricted to women and showed the same trend as studies covering both genders.
The study by Szczech et al. [59] as well as the study conducted by the Heart Protection Study Collaborative Group [43] evaluated patients with and without diabetes mellitus separately, but showed parameters of kidney failure to be a discriminating factor in both arms.
This section contains five study populations including more than 20 000 subjects, all convincingly underscoring a link of signs of enhanced cardiovascular damage with parameters corresponding to a decrease of renal function [34,43,60,90,100]. Two of these studies contained more than 100 000 subjects, but were conducted in the same study population [34,100].
Studies in populations selected on the presence of at least one traditional cardiovascular risk factor, including old age, or of chronic heart failure
Data are presented in Table 2.
In this section, 31 studies are included, representing 87 505 patients [20–31,44–47,62–65,103–113].
Table 2 is subdivided into three sections: (A) patients selected because of the presence of at least one cardiovascular risk factor (either hypertension or diabetes mellitus) (10 studies in 62 771 subjects; respectively, two and eight studies with diabetes and hypertension as determinant); (B) patients selected because of the presence of chronic heart failure or left ventricular dysfunction (13 studies in 18 262 subjects); and (C) patients selected because of old age (eight studies in 6472 subjects). Aged patients were confined to this part of the survey (corresponding to section C of Table 2) if no additional selection criterion was present. In Table 1 and sections A and B of Table 2, patient groups of similar old age are considered, but in these studies, patients were selected in addition because of the presence of at least one vessel lesion, one cardiovascular risk factor or chronic heart failure [22,25–27,29,31,34,35,37,54,55,60,86,89,91,93–96,99,100,105,108,110].
Of the 31 studies contained in this section, 16/31 (51.6%) had overall mortality as an endpoint, compared with 15/31 (48.4%) studies with cardiovascular morbidity or mortality as an endpoint. Considering these studies together, median age was 66.0 years (range: 39–77 years) and median follow-up time was 3.9 years (range: 0.4–10.0 years). The median cut-off value of renal function for showing increased cardiovascular risk was 63.9 ml/min for GFR or one of its surrogates (highest value: 90.0 ml/min) [65] and 1.3 mg/dl (115 µmol/l) for SCrea [lowest value overall: 0.9 mg/dl (80 µmol/l); in women: 0.79 mg/dl (70 µmol/l)] [31,45,106]. The results of 28 studies (90.3%) were adjusted for other cardiovascular risk factors.
To the best of our knowledge, the very first study to describe a relationship between parameters of kidney function and CVD is included in this section and was published by Bulpitt et al. in 1986 [20].
The largest population in this section was reported by Ruilope et al. (n = 18 790) [62] in a reanalysis of the Hypertension Optimal Treatment (HOT) Study.
In the study by Opasich et al. [28], patients with chronic congestive heart failure and a SCrea >2.5 mg/dl (>220 µmol/l) had a markedly higher mortality. This is the only study in this section where the difference in mortality was not significant, possibly because of the low number of patients with parameters corresponding to kidney failure (2.8% of the population; n = 93).
Studies in unselected populations
Data are presented in Table 3.
In this section, 14 studies are included, representing a total of 39 441 patients [6,48–51,58,114–121]. Of note, in all studies reported in Tables 1 and 2 and in seven of the 14 studies in Table 3, the enrolment in different strata is based on a single determination of SCrea, GFR or surrogate of GFR. These levels do not necessarily correspond to different degrees of severity of chronic kidney dysfunction, as they might have been influenced by instant factors, such as (de)hydratation, drug intake (non-steroidal anti-inflammatory drugs or angiotensin-converting enzyme inhibitors), recent radio-contrast investigations, etc. The seven studies of this type in Table 3 are classified under ‘kidney dysfunction not defined’ (35 214 subjects). Six studies covering 4227 subjects are based on defined CKD and are considered separately [6,48–50,120,121].
Considering these studies together, the median age of the patients was 55.5 years (range: 50–65 years) (i.e. markedly younger than in the previous sections A and B) and the median follow-up time was 9.85 years (range: 5.4–16.1 years) (i.e. markedly longer than in the previous sections). The median cut-off value of renal function linked to increased cardiovascular risk was 72.2 ml/min for GFR or one of its surrogates (highest value: 90.0 ml/min) [117,119] and 1.42 mg/dl (126.0 µmol/l) for SCrea [lowest value overall: 1.31 mg/dl (116 µmol/l); in women: 1.18 mg/dl (104 µmol/l)] [114,116]. The results of 10 studies (71.4%) were adjusted for other cardiovascular risk factors.
In the study by Culleton et al. [115], an impact of mild changes in renal function parameters on overall mortality was found only in men. This partial gender-related lack of significance might, in part, be attributed to the small number of patients with renal dysfunction in the gender strata (n = 270 for women).
Garg et al. [116] undertook an analysis of the data from the first National Health and Nutrition Examination Study (NHANES I) in 2352 adults. The hazard ratio related to moderate indices of kidney failure lost significance after correction for traditional risk factors. This is the only study included in the present survey, where a loss of significance after adjustment is observed.
When in more recent studies GFR was used as a renal function index, a relation of cardiovascular risk with kidney failure parameters was corroborated each time [117–119].
Also in the study by Abramson et al. [51], GFR-defined chronic renal failure resulted in a higher incidence of stroke, but most strikingly if combined with anaemia. Similar results were published, based on the same population, for risk of coronary events [58]. Of note, in at least four other studies, however, adjustment for anaemia did not neutralize the statistical weight of renal failure [47,54,65,85].
Overall summary of the data
Overall, 552 258 subjects were considered in 85 studies. All studies based on larger population sizes (>5000 subjects) [20,30,34,43,47,51,58,60,62,63,85,88,90–93, 99, 100,103,105,111–114,117,119] and/or based on adequate parameters of kidney function (GFR) [20,23, 24,29,30,37–41,44,46,48–56,60,62,64,65,85,87,91,92,94, 96,98–100,103,104,107,113,117–119,121] showed a significant relationship between the markers of renal dysfunction and overall mortality and/or cardiovascular morbidity or mortality.
One of the most relevant findings of this analysis is that the increase in cardiovascular risk occurs very early during the evolution of chronic renal failure (Figure 1), irrespective of the method of determination of renal function.
In 40 studies (Table 1), subjects were selected because of the presence of at least one cardiovascular abnormality, whereas in 31 other studies (Table 2), subjects were selected because of the presence of at least one traditional risk factor, including old age, or chronic heart failure. One might argue that this type of selection does not relate to kidney dysfunction per se. Of note, however, most of the patients attending nephrology clinics have similar comorbidities. In addition, results were similar in 14 studies in unselected populations (Table 3). In these populations, the hidden presence of the above-mentioned risk factors is not excluded, however. The results in these low cardiovascular risk populations with well-defined CKD point in the same direction of enhanced risk related to kidney dysfunction as the studies in the remaining populations. However, the link is somewhat less straightforward.
It is of note that studies from all over the world came to the same conclusion. In addition to Europe and Northern America, which are the most common geographical areas where this type of study is conducted, reports from China [31], Israel [46] and New Zealand [32] are also included. Hence, the relation between kidney dysfunction and cardiovascular risk seems to be universal.
Some of the enclosed studies were not undertaken primarily to evaluate the connection between kidney dysfunction and cardiovascular problems, but were e.g. evaluations of drug effects, which amongst other elements contained a comparison between patients with and without kidney dysfunction [20–22, 26,28,33,34,37,43]. Also, these studies came to the same conclusions as those specifically considering the relationship of kidney dysfunction and cardiovascular risk.
It might be argued that even if in total more than 550 000 subjects were considered in the 85 publications reported, the fraction of patients with kidney dysfunction contained in these studies might be much smaller, if not irrelevant. For that reason, the specific number of subjects with parameters corresponding to kidney dysfunction was also considered. For this subanalysis, overall, data from 74 studies were available. Among those, 26% of subjects in total conformed with preset parameters corresponding to kidney dysfunction, defined as the stratum or the sum of strata characterized by a higher sCrea and/or a lower GFR than the reference (control) group. If we accept that the vast majority of these study populations are recruited among subjects with at least one known cardiovascular problem [Tables 1 and 2 (section B)] or cardiovascular risk factor (Table 2, sections A and C), it might be hypothesized from the above that approximately one-quarter of these populations additionally suffer from a certain degree of renal dysfunction which only adds to their cardiovascular risk.
Of note, 71 of the 85 studies under consideration were adjusted for other cardiovascular risk factors. In only one study was the significant weight of renal failure lost [116].
Discussion
Our present study showed that (i) in the presence of an increased SCrea or a decreased GFR, morbidity and mortality because of CVD are markedly increased and vascular degradation is accelerated; (ii) the process of cardiovascular damage starts very early during progression in well-defined CKD, long before the dialysis stage is reached; (iii) the link between kidney dysfunction and CVD is an important global epidemiological entity with an extent comparable to the link observed between CVD and diabetes mellitus; (iv) apart from traditional cardiovascular risk factors, non-traditional factors specifically related to kidney failure per se, are very likely to play a causative role; and (v) adequate preventive measures against CVD should be started early during the natural history of kidney dysfunction, but their application is hampered by the incorrect interpretation of renal function parameters, the delayed identification of kidney failure and the (too) late referral of patients with kidney dysfunction.
Methodological considerations regarding the analysed literature
A substantial proportion of the cited studies are post-hoc analyses of interventional trials or observational studies. In this section, methodological aspects related to study design and choice of outcome variables are discussed. These more likely obscured or weakened rather than amplified the association of impaired renal function with CVD.
Retrospective analyses of the effect of a variable (in this case a renal function parameter) on the endpoints are generally underpowered, because these studies were not designed to detect such effects. Since renal failure per se enhances certain traditional risk factors, adjusted risks or hazard ratios may overcorrect for these factors and equally will underestimate a true relationship.
In most studies, a single determination of a surrogate marker for GFR is studied. A well-known problem with single determinations is regression dilution bias, a statistical phenomenon whereby the extreme values of high and low GFR (or surrogates) are more likely to over- or underestimate the real values; thus, once more attenuating the relationship of increasing cardiovascular risk with decreasing renal function. The frequently used surrogate markers for GFR, such as sCrea, may be increased by multiple instant factors, whereas an artefactual decrease is rare and in essence only related to spurious cases of fluid overload. This unequal distribution of errors may increase the scatter in the relationship with cardiovascular risk. Attempts to overcome this problem by calculating GFR causes the difficulty that known cardiovascular risk factors, such as age, weight and gender, are included a second time as predictor variables, so that the use of classical multivariate methods probably overcorrects for these factors. Categorization (renal failure or not) of a continuous variable (GFR) generally further decreases the power to detect a relationship with the outcome variable. Additionally, most studies a priori assume a linear relationship between GFR and CVD risk. The lack of exploration of non-linear relationships and interactions between chronic renal failure and other factors may result in a larger scatter (and weaker relationship) of the data when fitting the statistical model.
It is known that creatinine values vary across clinical laboratories and that all estimates of GFR from creatinine equations (Cockroft and Gault or MDRD formula) result in biased estimates if the sCrea assay used in a specific study is calibrated differently from that in the study which validated the method for estimating GFR. Systematic bias is relatively unimportant in investigations of the relationship between CVD and renal function within a study, but hampers comparison across studies and limits the interpretation of specific GFR cut-off points.
In addition, it should be realized that, apart from these drawbacks, sCrea is only a crude index of renal function and that GFR values, even if calculated, are more valid. For that reason, the method of renal function estimation was clearly specified in the tables. Studies based on sCrea were not excluded, however, to avoid selection bias (see ‘Subjects and methods’).
Studies considering mortality instead of cardiovascular morbidity as the endpoint may also lose power to detect a relationship, since mortality rates are much lower than cardiovascular incidence rates. Moreover, when all-cause mortality is considered rather than cardiovascular mortality, the relationship may become blurred by non-cardiovascular deaths.
Altogether, multiple aspects related to methodological design may influence the results in a way that they tend to weaken rather than strengthen the relationship between renal dysfunction and CVD. That such a strong relationship is nevertheless found only further corroborates the impact of this pathophysiological association.
Practical epidemiological considerations
After it had been established that dialysis patients are prone to accelerated atheromatosis [1], it has been suggested more recently that the cardiovascular system becomes affected in renal failure well before the stage of dialysis is reached [122]. This suggestion is strongly corroborated by this present survey. The smallest impairments in renal function associated with a significant increase in cardiovascular risk are a GFR of 90 ml/min/1.73 m2 [39,65,117,119] and a sCrea of 0.90 mg/dl (80 µmol/l) (Figure 1) [31,45,61]. The median cut-off GFR in each of Tables 1–3 was situated at ≥60 ml/min/1.73 m2, which corresponds to a loss of kidney function by a maximum 50%.
This problem of cardiovascular risk associated with kidney dysfunction, hence, affects a larger section of the general population than until recently suspected (Table 4). Based on recent data collected in the United States, ∼4.7% of the overall population suffers from a deterioration of GFR by ≥50% [123]. The vast majority of those (92%) has a GFR between 60 and 30 ml/min (CKD stage 3), of whom >90% are non-diabetics [123]. One should be careful with extrapolating these data from the USA to the rest of the world, but, unfortunately, to the best of our knowledge, no data from outside the USA are available as yet. However, even if the number of patients at risk would be substantially lower outside the USA, which is rather unlikely, the group size of potentially affected individuals seems to be not much different from those attributed to diabetes mellitus [124,125]. In spite of this, the cardiovascular risk associated with kidney dysfunction is not always recognized as such by society and even not by the nephrological community. Extending this problem to a population which is much larger than the group currently treated by dialysis also extends the socio-economic implications (Table 4) and underscores the urgent need for intervention to detect kidney dysfunction and to intensify the management of CVD when it is present.
. | Worldwide . | USA . | Europe . |
---|---|---|---|
Overall population | 6 000 000 000 | 389 000 000 | 800 000 000 |
GFR<60 ml/min (4.7%)b | 282 000 000 | 18 283 000 | 37 600 000 |
Stage 5 (ESRDc) | 1 750 000 | 335 000 | 350 000 |
. | Worldwide . | USA . | Europe . |
---|---|---|---|
Overall population | 6 000 000 000 | 389 000 000 | 800 000 000 |
GFR<60 ml/min (4.7%)b | 282 000 000 | 18 283 000 | 37 600 000 |
Stage 5 (ESRDc) | 1 750 000 | 335 000 | 350 000 |
. | Worldwide . | USA . | Europe . |
---|---|---|---|
Overall population | 6 000 000 000 | 389 000 000 | 800 000 000 |
GFR<60 ml/min (4.7%)b | 282 000 000 | 18 283 000 | 37 600 000 |
Stage 5 (ESRDc) | 1 750 000 | 335 000 | 350 000 |
. | Worldwide . | USA . | Europe . |
---|---|---|---|
Overall population | 6 000 000 000 | 389 000 000 | 800 000 000 |
GFR<60 ml/min (4.7%)b | 282 000 000 | 18 283 000 | 37 600 000 |
Stage 5 (ESRDc) | 1 750 000 | 335 000 | 350 000 |
Most patients with kidney dysfunction also bear one or more traditional cardiovascular risk factors and a major pathophysiological role might be attributed to these factors [126,127]. They undeniably have a negative clinical impact and should, if possible, be treated appropriately. In several correlation analyses, however, the statistical weight of traditional risk factors was weak to absent [50,105,128,129]. While submitting the uraemia population to a Framingham risk analysis, the real observed risk is far greater than the calculated one based on the traditional risk factors [121,128,130,131], which hardly differs from the risk in the general population [121,128,131]. Statistical adjustment for a host of comorbid factors in 71 studies does not neutralize the relation of cardiovascular risk with renal failure [6,20,23,24,26–35,38,40–42,44–48,51–65,85,87–115,117–119].
The risk factors which were most frequently adjusted were age (69/71 studies), gender (56), diabetes mellitus (55), vascular disease (52), blood pressure (49), left ventricular dysfunction (49), medication (39), smoking (36) and lipid status (32). Therefore, it is likely that non-traditional risk factors (as yet identified as well as non-identified) are at play as well.
Prominent candidates in such a role are uraemic retention solutes [128], which accumulate because the kidneys fail to eliminate them. Their accumulation in kidney failure might impose a mechanistically similar damaging effect as the one provoked by glycation products in diabetes [132]. Interestingly, several supportive studies suggest a relation between uraemic retention solutes and CVD: oxidative stress products [133–137]; pro-coagulant factors [48,135,138]; interleukin-6 [139]; phosphate and calcium–phosphate product [140–143]; asymmetric dimethylarginine [144,145]; parathyroid hormone [146,147]; neuropeptide Y [148]; homocysteine [48,149–154]. Also, sympathetic overactivity plays a prominent pathophysiological role [155].
However, at present, the evaluation of the factors responsible for increased CVD is far from complete and has been concentrated on those factors that had already been incriminated in the general population. It seems very much appropriate to extend our studies to those factors specific for renal failure. Recently identified but until then unsuspected compounds, such as phenylacetic acid, indoxyl sulphate, guanidine, methylguanidine, guanidinosuccinic acid, guanidinoacetic acid and p-cresol [156–158], underscore that many responsible compounds might have, as yet, gone unrecognized. Therefore, a more systematic evaluation and classification of known uraemic solutes [159] should be undertaken, to allow the development of more directed therapeutic approaches.
This review was conducted to make an objective evaluation in how many available studies in the literature the link between kidney dysfunction and CVD was confirmed. Confirmation was obtained from 85 studies covering more than 550 000 subjects, clearly showing this relationship, independent of geographic or ethnic factors. Differences in cardiovascular risk are already present at the very early phase of renal impairment; those can only be detected by sensitive methods of renal function assessment (GFR), which are therefore necessary and fully justified.
The epidemiological features observed bring this problem to the highest level of importance, along with other major conditions, such as diabetes mellitus and hypertension.
Much remains to be done, however, to improve the prevention of CVD associated with renal failure. The main aspects, with a predictable positive impact, that require our particular attention include:
Sensibilization regarding the problem and improvement of the awareness about its existence.
Inclusion in the follow-up of patients with cardiovascular risk of sensitive parameters assessing renal function and in patients with kidney dysfunction of parameters of cardiovascular risk.
Improvement of the interpretation of parameters of kidney (dys)function.
Sensibilization of the general population and general practitioners and improvement of collaboration between all healthcare providers to facilitate a timely referral of these patients to the nephrologist.
Application of the rules of secondary prevention in the presence of even moderate renal dysfunction.
The European Uremic Toxin Work Group (EUTox) is a group of European researchers involved in studies and reviews related to uraemic toxicity. The group was created under the auspices of the European Society for Artificial Organs (ESAO) and its members are A. Argiles, Montpellier, France; J. Beige, Leipzig, Germany; P. Brunet, Marseille, France; G. Cohen, Vienna, Austria; P.P. De Deyn, Antwerp, Belgium; B. Descamps-Latscha, Paris, France; S. Herget-Rosenthal, Essen, Germany; W. Hörl, Vienna, Austria; J. Jankowski, Berlin, Germany; A. Jörres, Berlin, Germany; Z.A. Massy, Amiens, France; M. Rodriguez, Cordoba, Spain; G. Spasovski, Skopje, Macedonia; B. Stegmayr, Umeå, Sweden; P. Stenvinkel, Stockholm, Sweden; R. Vanholder, Gent, Belgium; C. Wanner, Würzburg, Germany; E. Weissinger, Hannover, Germany; A. Wiecek, Katowice, Poland; W. Zidek, Berlin, Germany. The actions of this group are endorsed by the following companies: Amgen, Baxter Healthcare, Fresenius Medical Care, Gambro, Genzyme, Membrana and Roche.
Conflict of interest statement. None declared.
References
Lindner A, Charra B, Sherrard DJ, Scribner BH. Accelerated atherosclerosis in prolonged maintenance hemodialysis.
Foley RN, Parfrey PS, Sarnak MJ. Epidemiology of cardiovascular disease in chronic renal disease.
Goodman WG, Goldin J, Kuizon BD et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis.
Seliger SL, Gillen DL, Longstreth WT,Jr, Kestenbaum B, Stehman-Breen CO. Elevated risk of stroke among patients with end-stage renal disease.
Collins AJ, Li S, Gilbertson DT et al. Chronic kidney disease and cardiovascular disease in the Medicare population.
Drey N, Roderick P, Mullee M, Rogerson M. A population-based study of the incidence and outcomes of diagnosed chronic kidney disease.
Best PJ, Holmes DR, Jr. Chronic kidney disease as a cardiovascular risk factor.
Herzog CA, Ma JZ, Collins AJ. Poor long-term survival after acute myocardial infarction among patients on long-term dialysis.
Herzog CA. Acute myocardial infarction in patients with end-stage renal disease.
Reddan DN, Marcus RJ, Owen WF,Jr, Szczech LA, Landwehr DM. Long-term outcomes of revascularization for peripheral vascular disease in end-stage renal disease patients.
Holland DC, Lam M. Predictors of hospitalization and death among pre-dialysis patients: a retrospective cohort study.
Moeller S, Gioberge S, Brown G. ESRD patients in 2001: global overview of patients, treatment modalities and development trends.
Herzog CA. How to manage the renal patient with coronary heart disease: the agony and the ecstasy of opinion-based medicine.
Sarnak MJ, Levey AS, Schoolwerth AC et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention.
Coresh J, Astor B, Sarnak MJ. Evidence for increased cardiovascular disease risk in patients with chronic kidney disease.
Pinkau T, Hilgers KF, Veelken R, Mann JF. How does minor renal dysfunction influence cardiovascular risk and the management of cardiovascular disease?
Ritz E, McClellan WM. Overview: increased cardiovascular risk in patients with minor renal dysfunction: an emerging issue with far-reaching consequences.
Bulpitt CJ, Beevers DG, Butler A et al. The survival of treated hypertensive patients and their causes of death: a report from the DHSS Hypertensive Care Computing Project (DHCCP).
Packer M, Carver JR, Rodeheffer RJ et al. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group.
Madsen BK, Hansen JF, Stokholm KH et al. Chronic congestive heart failure. Description and survival of 190 consecutive patients with a diagnosis of chronic congestive heart failure based on clinical signs and symptoms.
Spinar J, Vitovec J, Spac J et al. Non-invasive prognostic factors in chronic heart failure. One-year survival of 300 patients with a diagnosis of chronic heart failure due to ischemic heart disease or dilated cardiomyopathy.
Rossing P, Hougaard P, Borch-Johnsen K, Parving HH. Predictors of mortality in insulin dependent diabetes: 10 year observational follow up study.
Pahor M, Shorr RI, Somes GW et al. Diuretic-based treatment and cardiovascular events in patients with mild renal dysfunction enrolled in the systolic hypertension in the elderly program.
Feenstra J, in't Veld BA, van der Linden PD, Grobbee DE, Stricker BH. Risk factors for mortality in users of ibopamine.
McAlister FA, Teo KK, Taher M et al. Insights into the contemporary epidemiology and outpatient management of congestive heart failure.
Opasich C, Tavazzi L, Lucci D et al. Comparison of one-year outcome in women versus men with chronic congestive heart failure.
Cowie MR, Wood DA, Coats AJ et al. Survival of patients with a new diagnosis of heart failure: a population based study.
Al Ahmad A, Rand WM, Manjunath G et al. Reduced kidney function and anemia as risk factors for mortality in patients with left ventricular dysfunction.
Wang JG, Staessen JA, Fagard RH et al. Prognostic significance of serum creatinine and uric acid in older Chinese patients with isolated systolic hypertension.
Friedman PJ. Serum creatinine: an independent predictor of survival after stroke.
Nygard O, Nordrehaug JE, Refsum H et al. Plasma homocysteine levels and mortality in patients with coronary artery disease.
Gottlieb SS, McCarter RJ, Vogel RA. Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction.
Ting HH, Tahirkheli NK, Berger PB et al. Evaluation of long-term survival after successful percutaneous coronary intervention among patients with chronic renal failure.
Asinger RW, Henry TD, Herzog CA, Paulsen PR, Kane RL. Clinical outcomes of PTCA in chronic renal failure: a case-control study for comorbid features and evaluation of dialysis dependence.
Januzzi JL,Jr, Snapinn SM, DiBattiste PM, Jang IK, Theroux P. Benefits and safety of tirofiban among acute coronary syndrome patients with mild to moderate renal insufficiency: results from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) trial.
Zebrack JS, Anderson JL, Beddhu S et al. Do associations with C-reactive protein and extent of coronary artery disease account for the increased cardiovascular risk of renal insufficiency?
Reddan DN, Szczech LA, Tuttle RH et al. Chronic kidney disease, mortality, and treatment strategies among patients with clinically significant coronary artery disease.
Keeley EC, Kadakia R, Soman S, Borzak S, McCullough PA. Analysis of long-term survival after revascularization in patients with chronic kidney disease presenting with acute coronary syndromes.
Conlon PJ, Athirakul K, Kovalik E et al. Survival in renal vascular disease.
Naidu SS, Selzer F, Jacobs A et al. Renal insufficiency is an independent predictor of mortality after percutaneous coronary intervention.
MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial.
Damsgaard EM, Froland A, Jorgensen OD, Mogensen CE. Microalbuminuria as predictor of increased mortality in elderly people.
Alcorn HG, Wolfson SK,Jr, Sutton-Tyrrell K, Kuller LH, O'Leary D. Risk factors for abdominal aortic aneurysms in older adults enrolled in The Cardiovascular Health Study.
Bursztyn M, Ginsberg G, Spilberg O, Maaravi Y, Stessman J. Mortality in the Jerusalem 70-year-olds longitudinal study: does nifedipine have a role?
Fried LF, Shlipak MG, Crump C et al. Renal insufficiency as a predictor of cardiovascular outcomes and mortality in elderly individuals.
Jungers P, Massy ZA, Khoa TN et al. Incidence and risk factors of atherosclerotic cardiovascular accidents in pre-dialysis chronic renal failure patients: a prospective study.
Jungers P, Nguyen KT, Massy ZA, Man NK. Incidence des accidents cardio-vasculaires d'origine athéromateuse chez l'urémique chronique: études épidemiologiques en Ile-de-France.
Levin A, Djurdjev O, Barrett B et al. Cardiovascular disease in patients with chronic kidney disease: getting to the heart of the matter.
Abramson JL, Jurkovitz CT, Vaccarino V, Weintraub WS, McClellan W. Chronic kidney disease, anemia, and incident stroke in a middle-aged, community-based population: the ARIC Study.
Sadeghi HM, Stone GW, Grines CL et al. Impact of renal insufficiency in patients undergoing primary angioplasty for acute myocardial infarction.
McCullough PA, Nowak RM, Foreback C et al. Emergency evaluation of chest pain in patients with advanced kidney disease.
Langston RD, Presley R, Flanders WD, McClellan WM. Renal insufficiency and anemia are independent risk factors for death among patients with acute myocardial infarction.
Scolari F, Ravani P, Pola A et al. Predictors of renal and patient outcomes in atheroembolic renal disease: a prospective study.
Hillege HL, van Gilst WH, van Veldhuisen DJ et al. Accelerated decline and prognostic impact of renal function after myocardial infarction and the benefits of ACE inhibition: the CATS randomized trial.
Kaplan RC, Heckbert SR, Furberg CD, Psaty BM. Predictors of subsequent coronary events, stroke, and death among survivors of first hospitalized myocardial infarction.
Jurkovitz CT, Abramson JL, Vaccarino LV, Weintraub WS, McClellan WM. Association of high serum creatinine and anemia increases the risk of coronary events: results from the prospective community-based Atherosclerosis Risk in Communities (ARIC) Study.
Szczech LA, Best PJ, Crowley E et al. Outcomes of patients with chronic renal insufficiency in the bypass angioplasty revascularization investigation.
Al Suwaidi J, Reddan DN, Williams K et al. Prognostic implications of abnormalities in renal function in patients with acute coronary syndromes.
Matts JP, Karnegis JN, Campos CT et al. Serum creatinine as an independent predictor of coronary heart disease mortality in normotensive survivors of myocardial infarction. POSCH Group.
Ruilope LM, Salvetti A, Jamerson K et al. Renal function and intensive lowering of blood pressure in hypertensive participants of the Hypertension Optimal Treatment (HOT) Study.
Shulman NB, Ford CE, Hall WD et al. Prognostic value of serum creatinine and effect of treatment of hypertension on renal function. Results from the Hypertension Detection and Follow-up Program. The Hypertension Detection and Follow-up Program Cooperative Group.
Flack JM, Neaton JD, Daniels B, Esunge P. Ethnicity and renal disease: lessons from the Multiple Risk Factor Intervention Trial and the Treatment of Mild Hypertension Study.
Manjunath G, Tighiouart H, Coresh J et al. Level of kidney function as a risk factor for cardiovascular outcomes in the elderly.
Rao V, Weisel RD, Buth KJ et al. Coronary artery bypass grafting in patients with non-dialysis-dependent renal insufficiency.
Freeman RV, Mehta RH, Al Badr W et al. Influence of concurrent renal dysfunction on outcomes of patients with acute coronary syndromes and implications of the use of glycoprotein IIb/IIIa inhibitors.
Santopinto JJ, Fox KA, Goldberg RJ et al. Creatinine clearance and adverse hospital outcomes in patients with acute coronary syndromes: findings from the Global Registry of Acute Coronary Events (GRACE).
Liu JY, Birkmeyer NJ, Sanders JH et al. Risks of morbidity and mortality in dialysis patients undergoing coronary artery bypass surgery. Northern New England Cardiovascular Disease Study Group.
Anderson RJ, O'Brien M, MaWhinney S et al. Mild renal failure is associated with adverse outcome after cardiac valve surgery.
O'Brien MM, Gonzales R, Shroyer AL et al. Modest serum creatinine elevation affects adverse outcome after general surgery.
Kennedy DJ, Colyer WR, Brewster PS et al. Renal insufficiency as a predictor of adverse events and mortality after renal artery stent placement.
Moscucci M, Kline-Rogers E, Share D et al. Simple bedside additive tool for prediction of in-hospital mortality after percutaneous coronary interventions.
Shaw RE, Anderson HV, Brindis RG et al. Development of a risk adjustment mortality model using the American College of Cardiology–National Cardiovascular Data Registry (ACC–NCDR) experience: 1998–2000.
Powell RJ, Roddy SP, Meier GH et al. Effect of renal insufficiency on outcome following infrarenal aortic surgery.
Soman SS, Sandberg KR, Borzak S et al. The independent association of renal dysfunction and arrhythmias in critically ill patients.
Gottdiener JS, Arnold AM, Aurigemma GP et al. Predictors of congestive heart failure in the elderly: the Cardiovascular Health Study.
Chae CU, Albert CM, Glynn RJ, Guralnik JM, Curhan GC. Mild renal insufficiency and risk of congestive heart failure in men and women ≥70 years of age.
Wang F, Dupuis JY, Nathan H, Williams K. An analysis of the association between preoperative renal dysfunction and outcome in cardiac surgery: estimated creatinine clearance or plasma creatinine level as measures of renal function.
Meier-Kriesche HU, Baliga R, Kaplan B. Decreased renal function is a strong risk factor for cardiovascular death after renal transplantation.
Abbott KC, Yuan CM, Taylor AJ, Cruess DF, Agodoa LY. Early renal insufficiency and hospitalized heart disease after renal transplantation in the era of modern immunosuppression.
Ojo AO, Held PJ, Port FK et al. Chronic renal failure after transplantation of a nonrenal organ.
Gerstein HC, Mann JF, Yi Q et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals.
Anderson RJ, O'Brien M, MaWhinney S et al. Renal failure predisposes patients to adverse outcome after coronary artery bypass surgery. VA Cooperative Study #5.
McCullough PA, Soman SS, Shah SS et al. Risks associated with renal dysfunction in patients in the coronary care unit.
Rubenstein MH, Harrell LC, Sheynberg BV et al. Are patients with renal failure good candidates for percutaneous coronary revascularization in the new device era?
Beattie JN, Soman SS, Sandberg KR et al. Determinants of mortality after myocardial infarction in patients with advanced renal dysfunction.
Hemmelgarn BR, Ghali WA, Quan H et al. Poor long-term survival after coronary angiography in patients with renal insufficiency.
Shlipak MG, Simon JA, Grady D et al. Renal insufficiency and cardiovascular events in postmenopausal women with coronary heart disease.
Szczech LA, Reddan DN, Owen WF et al. Differential survival after coronary revascularization procedures among patients with renal insufficiency.
Best PJ, Lennon R, Ting HH et al. The impact of renal insufficiency on clinical outcomes in patients undergoing percutaneous coronary interventions.
Beddhu S, Allen-Brady K, Cheung AK et al. Impact of renal failure on the risk of myocardial infarction and death.
Gruberg L, Weissman NJ, Waksman R et al. Comparison of outcomes after percutaneous coronary revascularization with stents in patients with and without mild chronic renal insufficiency.
Wright RS, Reeder GS, Herzog CA et al. Acute myocardial infarction and renal dysfunction: a high-risk combination.
Walsh CR, O'Donnell CJ, Camargo CA,Jr, Giugliano RP, Lloyd-Jones DM. Elevated serum creatinine is associated with 1-year mortality after acute myocardial infarction.
Gruberg L, Weissman NJ, Pichard AD et al. Impact of renal function on morbidity and mortality after percutaneous aortocoronary saphenous vein graft intervention.
Reinecke H, Trey T, Matzkies F et al. Grade of chronic renal failure, and acute and long-term outcome after percutaneous coronary interventions.
Wison S, Foo K, Cunningham J et al. Renal function and risk stratification in acute coronary syndromes.
Sorensen CR, Brendorp B, Rask-Madsen C et al. The prognostic importance of creatinine clearance after acute myocardial infarction.
Shlipak MG, Heidenreich PA, Noguchi H et al. Association of renal insufficiency with treatment and outcomes after myocardial infarction in elderly patients.
Brooks MM, Jones RH, Bach RG et al. Predictors of mortality and mortality from cardiac causes in the Bypass Angioplasty Revascularization Investigation (BARI) randomized trial and registry. For the BARI Investigators.
Reis SE, Olson MB, Fried L et al. Mild renal insufficiency is associated with angiographic coronary artery disease in women.
Dries DL, Exner DV, Domanski MJ, Greenberg B, Stevenson LW. The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction.
Hillege HL, Girbes AR, de Kam PJ et al. Renal function, neurohormonal activation, and survival in patients with chronic heart failure.
Mann JF, Gerstein HC, Pogue J, Bosch J, Yusuf S. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial.
Schillaci G, Reboldi G, Verdecchia P. High-normal serum creatinine concentration is a predictor of cardiovascular risk in essential hypertension.
Mahon NG, Blackstone EH, Francis GS et al. The prognostic value of estimated creatinine clearance alongside functional capacity in ambulatory patients with chronic congestive heart failure.
de Leeuw PW, Thijs L, Birkenhager WH et al. Prognostic significance of renal function in elderly patients with isolated systolic hypertension: results from the Syst-Eur trial.
Kearney MT, Fox KA, Lee AJ et al. Predicting death due to progressive heart failure in patients with mild-to-moderate chronic heart failure.
McClellan WM, Flanders WD, Langston RD, Jurkovitz C, Presley R. Anemia and renal insufficiency are independent risk factors for death among patients with congestive heart failure admitted to community hospitals: a population-based study.
Manolio TA, Kronmal RA, Burke GL, O'Leary DH, Price TR. Short-term predictors of incident stroke in older adults. The Cardiovascular Health Study.
Fried LP, Kronmal RA, Newman AB et al. Risk factors for 5-year mortality in older adults: the Cardiovascular Health Study.
Shlipak MG, Fried LF, Crump C et al. Cardiovascular disease risk status in elderly persons with renal insufficiency.
Wannamethee SG, Shaper AG, Perry IJ. Serum creatinine concentration and risk of cardiovascular disease: a possible marker for increased risk of stroke.
Culleton BF, Larson MG, Wilson PW et al. Cardiovascular disease and mortality in a community-based cohort with mild renal insufficiency.
Garg AX, Clark WF, Haynes RB, House AA. Moderate renal insufficiency and the risk of cardiovascular mortality: results from the NHANES I.
Muntner P, He J, Hamm L, Loria C, Whelton PK. Renal insufficiency and subsequent death resulting from cardiovascular disease in the United States.
Henry RM, Kostense PJ, Bos G et al. Mild renal insufficiency is associated with increased cardiovascular mortality: the Hoorn Study.
Manjunath G, Tighiouart H, Ibrahim H et al. Level of kidney function as a risk factor for atherosclerotic cardiovascular outcomes in the community.
Landray MJ, Thambyrajah J, McGlynn FJ et al. Epidemiological evaluation of known and suspected cardiovascular risk factors in chronic renal impairment.
Sarnak MJ, Coronado BE, Greene T et al. Cardiovascular disease risk factors in chronic renal insufficiency.
Shoji T, Emoto M, Tabata T et al. Advanced atherosclerosis in predialysis patients with chronic renal failure.
Coresh J, Astor BC, Greene T, Eknoyan G, Levey AS. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey.
Harris MI, Flegal KM, Cowie CC et al. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in US adults. The Third National Health and Nutrition Examination Survey, 1988–1994.
Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic.
Uhlig K, Levey AS, Sarnak MJ. Traditional cardiac risk factors in individuals with chronic kidney disease.
Locatelli F, Pozzoni P, Tentori F, del Vecchio L. Epidemiology of cardiovascular risk in patients with chronic kidney disease.
Cheung AK, Sarnak MJ, Yan G et al. Atherosclerotic cardiovascular disease risks in chronic hemodialysis patients.
Fleischmann EH, Bower JD, Salahudeen AK. Are conventional cardiovascular risk factors predictive of two-year mortality in hemodialysis patients?
Zoccali C. Cardiovascular risk in uraemic patients: is it fully explained by classical risk factors?
Longenecker JC, Coresh J, Powe NR et al. Traditional cardiovascular disease risk factors in dialysis patients compared with the general population: the CHOICE Study.
Henle T, Miyata T. Advanced glycation end products in uremia.
Boaz M, Matas Z, Biro A et al. Serum malondialdehyde and prevalent cardiovascular disease in hemodialysis.
Boaz M, Smetana S, Weinstein T et al. Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial.
Boaz M, Matas Z, Biro A et al. Comparison of hemostatic factors and serum malondialdehyde as predictive factors for cardiovascular disease in hemodialysis patients.
Siems W, Quast S, Carluccio F et al. Oxidative stress in chronic renal failure as a cardiovascular risk factor.
Shoji T, Fukumoto M, Kimoto E et al. Antibody to oxidized low-density lipoprotein and cardiovascular mortality in end-stage renal disease.
Shlipak MG, Fried LF, Crump C et al. Elevations of inflammatory and procoagulant biomarkers in elderly persons with renal insufficiency.
Stenvinkel P, Heimburger O, Jogestrand T. Elevated interleukin-6 predicts progressive carotid artery atherosclerosis in dialysis patients: association with Chlamydia pneumoniae seropositivity.
London GM, Fabiani F, Marchais SJ et al. Uremic cardiomyopathy: an inadequate left ventricular hypertrophy.
Guerin AP, London GM, Marchais SJ, Metivier F. Arterial stiffening and vascular calcifications in end-stage renal disease.
Block GA, Hulbert-Shearon TE, Levin NW, Port FK. Association of serum phosphorus and calcium × phosphate product with mortality risk in chronic hemodialysis patients: a national study.
Block G, Port FK. Calcium phosphate metabolism and cardiovascular disease in patients with chronic kidney disease.
Zoccali C, Bode-Boger S, Mallamaci F et al. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study.
Zoccali C, Benedetto FA, Maas R et al. Asymmetric dimethylarginine, C-reactive protein, and carotid intima–media thickness in end-stage renal disease.
De Boer IH, Gorodetskaya I, Young B, Hsu CY, Chertow GM. The severity of secondary hyperparathyroidism in chronic renal insufficiency is GFR-dependent, race-dependent, and associated with cardiovascular disease.
Perkovic V, Hewitson TD, Kelynack KJ et al. Parathyroid hormone has a prosclerotic effect on vascular smooth muscle cells.
Zoccali C, Mallamaci F, Tripepi G et al. Prospective Study of Neuropeptide Y as an Adverse Cardiovascular Risk Factor in End-Stage Renal Disease.
Fellah H, Feki M, Hsairi M et al. Hyperhomocysteinemia and end-stage renal disease: determinants and association with cardiovascular disease in Tunisian patients.
Bostom AG, Shemin D, Verhoef P et al. Elevated fasting total plasma homocysteine levels and cardiovascular disease outcomes in maintenance dialysis patients. A prospective study.
Ducloux D, Motte G, Challier B, Gibey R, Chalopin JM. Serum total homocysteine and cardiovascular disease occurrence in chronic, stable renal transplant recipients: a prospective study.
Bostom AG, Culleton BF. Hyperhomocysteinemia in chronic renal disease.
Mallamaci F, Zoccali C, Tripepi G et al. Hyperhomocysteinemia predicts cardiovascular outcomes in hemodialysis patients.
Moustapha A, Naso A, Nahlawi M et al. Prospective study of hyperhomocysteinemia as an adverse cardiovascular risk factor in end-stage renal disease.
Rump LC, Amann K, Orth S, Ritz E. Sympathetic overactivity in renal disease: a window to understand progression and cardiovascular complications of uraemia?
Jankowski J, van der GM, Jankowski V et al. Increased plasma phenylacetic acid in patients with end-stage renal failure inhibits iNOS expression.
Dou L, Bertrand E, Cerini C et al. The uremic solutes p-cresol and indoxyl sulfate inhibit endothelial proliferation and wound repair.
Glorieux GL, Dhondt AW, Jacobs P et al. In vitro study of the potential role of guanidines in leukocyte functions related to atherogenesis and infection.
Author notes
1Nephrology Section, Department of Internal Medicine, University Hospital, Gent, Belgium, 2Divisions of Clinical Pharmacology and Nephrology, University of Picardie and Amiens, University Hospital, Amiens, France, 3Laboratory of Functional Genomics, UPR 2580 of CNRS, Montpellier, France and 4Department of Nephrology, Clinical Center, University Hospital, Skopje, Macedonia
Comments